Synergy Pharmaceuticals Inc. is a biopharmaceutical company that focuses on developing drugs for treating gastrointestinal (GI) disorders and diseases. Synergy’s lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist which has completed Phase IIa clinical trials for the treatment of chronic idiopathic constipation GI disorders and is in Phase IIb clinical trials for the treatment of constipation-predominant irritable bowel syndrome GI disorders. For more information, visit the company’s website at www.synergypharma.com.